PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Consensus Development Conference, NIH”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 55 records · Page 3Linked to original sources
PubMed1989

The impact of implants on dental practice. A review of the 1988 NIH Consensus Development Conference.

The Consensus Development Conference process for the second time in ten years has come to grips with the dynamic field of oral implantology and has given it unquestioned scientific legitimacy and clear future clinical and research direction. Hopefully, for the millions of patients who could benefit from implant therapies, practitioners, hospitals, academic institutions, government agencies, health care insurance carriers, etc. will not wait to be forced to confront the reality of the success of implants, but they will begin or continue to restructure their practices, curricula, health care policies and benefits to provide the quality of life reasonably desired by our citizens.

Dental Implantation↗
PubMed1985

[Adjuvant chemotherapy in breast cancer. Report and commentary on the NIH Consensus Development Conference, Bethesda, Maryland, U.S. 9-11 September, 1985].

Adjuvant chemo- and endocrine treatment in breast cancer are effective treatment modalities. However, the cure rate in this disease is still not satisfying. Using prospective clinical trials further treatment procedures should be evaluated. Based on data presented at the 1985 Consensus Development Conference, treatment recommendations can be made for patients, who are not willing to participate in clinical trials: Regardless of steroid hormone receptor status combination chemotherapy has proven significant effectiveness in premenopausal patients with axillary node metastases, however in patients without nodal involvement this treatment is generally not recommended. For patients with receptor-negative and/or undifferentiated carcinomas chemotherapy should be considered. Postmenopausal patients with axillary node metastases and receptor-positive tumours should be treated with tamoxifen. In those with positive nodes and negative receptors chemotherapy may be considered. There is no indication for routine adjuvant chemotherapy in postmenopausal patients with negative nodes regardless of hormone receptor levels.

Axilla↗